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Abstract Krabbe disease is a lysosomal storage disease
caused by galactosylceramidase deficiency, resulting in
neurodegeneration with a rapid clinical downhill course
within the first months of life in the classic infantile form.
This process may be triggered by the accumulation of
galactosylceramide (GalCer) in nervous tissues. Both the
enzyme galactosylceramidase and its in vivo activator
molecule, saposin A, are essential during GalCer degrada-
tion. A clinical manifestation almost identical to Krabbe
disease is observed when, instead of the galactosylcerami-
dase protein, the saposin A molecule is defective. Saposin
A results from posttranslational processing of the precursor
molecule, prosaposin, encoded by the PSAP gene. Clinical
and neuroimaging findings in a 7-month-old child strongly
suggested Krabbe disease, but this condition was excluded
by enzymatic and genetic testing. However, at whole
exome sequencing, the previously undescribed homo-
zygous, obviously pathogenic PSAP gene NM_002778.3:
c.209T>G(p.Val70Gly) variant was determined in the
saposin A domain of the PSAP gene. Fibroblast studies
showed GalCer accumulation and the activation of auto-
phagy for the first time in a case of human saposin A
deficiency. Our patient represents the second known case in
the literature and provides new information concerning the
pathophysiology of saposin A deficiency and its intra-
lysosomal effects.
Introduction
Lysosomal degradation of glycosphingolipids begins with
the cleavage of monosaccharide units from the nonreducing
ends of the oligosaccharide chain. This reaction is catalyzed
by exohydrolases exhibiting activity in acidic pH optima.
Several enzymes require glycoprotein molecules known as
low molecular weight activator proteins for these reactions
(Kolter and Sandhoff 2005; Sandhoff 2016)
Activator proteins are glycoproteins that provide the
structural modifications necessary for binding the enzyme
and substrate during degradation of lysosomal glycosphin-
golipids, which combine with the enzyme or the substrate
or sometimes with both. These permit selective degradation
of membrane lipids in the intraendosomal and intralyso-
somal membrane pool without compromise of lysosomal
integrity (Spiegel et al. 2005).
These proteins are divided into two main groups,
sphingolipid activator proteins (SAPs) and GM2 activator
protein (Kolter and Sandhoff 2005). With posttranslational
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modification, the molecule prosaposin encoded by the
PSAP gene is separated into four homologous mature
proteins – saposins A–D. These are acidic, enzymatically
inactive, thermostable, protease-resistant glycoproteins,
8–11 kDa in size. Despite all their structural similarities,
they possess distinct, specific activator functions
(Kishimoto et al. 1992).
Inherited activator protein function deficiency leads to
the accumulation of undegraded membrane glycosphingo-
lipids in the lysosomal compartments and to lysosomal
storage disease (Kolter and Sandhoff 2005). Saposin A is
responsible for the activation and stabilization of galacto-
sylceramide beta-galactosidase (GalCer degradation)
(Harzer et al. 1997; Morimoto et al. 1989; Pankiv et al.
2007) Deficiency of saposin A results in a Krabbe-like
manifestation (Kolter and Sandhoff 2005; Matsuda et al.
2001; Spiegel et al. 2005).
Rather than being the last stage in degradation, the
lysosome has been shown to have cellular functions. These
include coordinating several intracellular signal pathways,
including autophagy, a mechanism necessary for cellular
survival (Matsuda et al. 2001; Seranova et al. 2017;
Settembre et al. 2008). The impaired degradation mecha-
nism in lysosomal storage diseases compromises auto-
phagic flux, and this has been shown to be one of the
mechanisms in the etiopathogenesis of lysosomal storage
diseases (Lieberman et al. 2012). Mouse studies have been
performed on this subject, but there has been very little
examination of saposin A deficiency and its effect on
autophagy (Sun and Grabowski 2013).
We report a case of a newly described homozygous
mutation in the saposin A domain in the PSAP gene in an
infant exhibiting clinical findings of Krabbe disease. To the
best of our knowledge, this is the second case following
Spiegel et al.’s case report published in 2005, and the first
case to be reported from Turkey. This study also presents,
for the first time, autophagic findings in human saposin A
deficiency.
Material and Methods
Case Report
A 7-month-old girl, with first-degree consanguinity
between her parents, presented to our clinic due to
refractory convulsions. Head control was present at the
age of 1 month, but this was lost at the age of 4 months,
while feeding difficulty occurred at 5 months and
generalized tonic convulsions started at 6 months. At
examination on arrival, her head circumference was in the
3rd percentile, weight in the 3rd to 10th percentile, and
height in the 25th percentile. No marked dysmorphic
feature was observed, and no organomegaly was present.
Deep tendon reflexes were increased, and hypertonicity was
present. Ammonia, lactate, plasma amino acids, blood spot
carnitine and acylcarnitine, and urine organic acid analyses
were normal. Cerebrospinal fluid (CSF) proteins were
135 mg/dL (normal for age, 20–50 mg/dL). Bilateral
ventricular enlargement, hyperintense lesions in cerebral
white matter, and thickening in the optic nerves were
determined at cerebral imaging. No increase in cerebral
metabolites was observed at cerebral magnetic resonance
spectroscopy (Fig. 1). Severe axonal polyneuropathy was
determined by electromyography. Galactosylceramidase
enzyme analysis was performed due to compatibility with
Krabbe disease. Galactosylceramidase activity in dried
blood was low (Table 1). No mutation was determined at
GALC gene analysis performed due to clinical and cerebral
Fig. 1 Magnetic resonance imaging of the patient. (a) Axial T2
image; hyperintensity at the periventricular white matter and centrum
semiovale. (b) Axial T1 IR (inversion recovery) image; hypointensity
at the periventricular white matter and centrum semiovale. (c) Coronal
FLAIR image; hyperintensity at deep white matter, subcortical u-fiber
is spared. (d) Multivoxel proton MR spectroscopy; choline peak at the
level of right centrum semiovale
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imaging findings compatible with Krabbe disease. Intra-
leukocytic galactosylceramidase levels investigated for
confirmation of enzyme levels were low (Table 2). How-
ever, the patient’s intraleukocytic galactosylceramidase
enzyme activity was higher than the enzyme levels of
patients with Krabbe disease. When comparison with other
lysosomal enzymes was performed, glucocerebrosidase,
beta-galactosidase, hexosaminidase A, hexosaminidase B,
alpha-glucosidase, and sphingomyelinase enzyme levels
were normal. Assessed in the light of the MR and clinical
findings, the suspicion of Krabbe disease was very
powerful, but since no mutation was determined at genetic
analysis, whole exome sequencing was investigated with a
preliminary diagnosis of saposin A deficiency, known to
follow a similar clinical course to that of Krabbe disease. At
whole exome sequencing, the pathogenic NM_002778.3:
c.209T>G (p.Val70Gly) variant not previously described in
the PSAP gene was identified and determined as homo-
zygous. This pathogenic variant was confirmed at PSAP gene
investigation using Sanger sequencing. Eight pathogenic
predictions were demonstrated from DANN, GERP,
dbNSFP.FATHMM, MetaLR, MetaSVM, MutationAssessor,
MutationTaster, and PROVEAN (vs one benign prediction
from LRT) by in silico assessment tools. Allele was not found
in Broad gnomAD exomes. Screening of the patient’s mother,
father, and sibling identified the same pathogenic variant as
heterozygous. The patient’s and family members’ PSAP
mutation Sanger sequencing patterns and the patient’s
Integrative Genomics Viewer presentation are shown in
Fig. 2.
Biochemical Studies
Enzyme Assay
Galactosylceramidase activity was measured by UHPLC
MS/MS (Waters Acquity™ UPLC I-Class system) method
(Orsini et al. 2012). Substrate was kindly provided by
CDC.
Cell Culture
Fibroblasts were obtained from forearm skin with punch
biopsy. Fibroblasts were cultured and maintained in
DMEM high glucose (Gibco) supplemented with 20%
FBS (Gibco) and 1% (vol/vol) penicillin/streptomycin
(Gibco). Passage-matched fibroblasts (passages 3–5) were
used in all experiments.
Glycosphingolipid (GSL) Extraction and Thin Layer
Chromatography
GSLs were extracted from proband and healthy control
primary skin fibroblasts, separated and chemically stained as
described previously (Sandhoff et al. 2002) with minor
modifications. The cells were washed with 1 ! PBS and
resuspended in 1 mL distilled water. They were then
subjected to three successive rounds of freeze-thawing by
incubation in a "80#C freezer for 5 min and thawing in cold
water. The sample was sonicated for 3 min, followed by
lyophilization and extraction two times with 2 mL of acetone.
Table 1 Lysosomal enzymes (dry blood spot)
Enzyme (nmol/mL/h) Proband Mother Father Brother Normal values
Galactosylceramidase 0.2 1.1 0.88 0.97 0.55–3.55
Beta-hexosaminidase A 18 28.2 17 13.5 7–70
Beta-galactosidase 9.1 12.3 9.7 9.3 6–24
Table 2 Lysosomal enzymes in white blood cells
Enzyme Proband Father Mother Brother Normal values
Galactosylceramidase (nmol/17 h/mg protein) 3.74 21 23.6 32 Infantile Krabbe: 0–0.8
Adult Krabbe: 2.2–3.5
Arylsulphatase A (nmol/h/mg protein) 38.3 36.1 42 27.4 22–103
Beta-galactosidase (nmol/h/mg protein) 234 354 278.4 310 163–378
Tripeptidyl peptidase I (nmol/h/mg protein) 309 101 219 81.3 42–339
Palmitoyl protein thioesterase (nmol/h/mg protein) 57 26.2 102 94.3 17–139
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Fig. 2 Sanger sequencing images of proband (a), father (b), mother (c), brother (d), and Integrative Genomics Viewer presentation of PSAP gene
of proband (e)
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The pellets were re-extracted with solvent mixtures of
chloroform/methanol/water, twice in a ratio of 10:10:1 and
twice in a ratio of 30:60:8, and all supernatants were pooled.
Neutral GSLs were separated on DEAE A-25 as the flow-
through and methanol wash. The solvent was evaporated,
and the dried lipids were dissolved in the solvent mixture of
chloroform/methanol/water in a ratio of 10:10:1. TLC plates,
loaded with lipid extracts, were developed with chloroform/
methanol/0.2% aqueous CaCl2 (60/35/8) and then dried and
stained with orcinol to reveal sugar containing compounds.
Immunofluorescence
Proband and healthy control primary skin fibroblasts were
grown on microscope slides. The cells were washed with
1 ! PBS and fixed with 4% paraformaldehyde (PFA) for
30 min at room temperature. They were then washed three
times with PBS and permeabilized using PBS containing
0.3% TritonX100 at room temperature, followed by block-
ing for 1 h in PBS containing 10% goat serum and 0.3%
TritonX100. Anti-LAMP1 (1:500, abcam – ab24170),
Fig. 2 (continued)
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Anti-SQSTM1/p62 (1:500, Thermo – PA5–20839), and
Anti-hLC3/MAP 1LCA (1:20, R&D Systems – MAB8558)
primary antibody incubation was performed overnight at
4#C. The cells were extensively washed with PBS contain-
ing 0.05% Tween 20. Alexa Fluor 488-conjugated goat
anti-rabbit (1:500, Abcam – ab150077) and Alexa Fluor
568-conjugated goat anti-rat (1:250-Abcam- ab175476)
secondary antibody incubation was performed for 1 h
at room temperature. The cells were mounted with
Fluoroshield mounting medium with 40,6-diamidino-2-
phenylindole (DAPI, Abcam – ab104139). Images were
acquired by fluorescence microscopy (OLYMPUS). Coloc-
alization analysis between p62 and LC3A and between
LC3A and LAMP1 was performed using Coloc 2 based on
Pearson’s coefficients on ImageJ.
Statistical Analysis
GraphPad statistical software was used for statistical ana-
lysis. All values are expressed as mean $ S.E.M. Differ-
ences were tested using one-way ANOVA. A p-value of
less than 0.05 was considered statistically significant.
Results
Altered Ganglioside Pattern in Saposin A-Deficient
Fibroblasts
We showed the levels of neutral glycosphingolipids in
fibroblasts from saposin A patient (proband) and healthy
family members using thin layer chromatography (Fig. 3a).
We detected significant increases in the levels of GalCer
(Fig. 3b), LacCer (Fig. 3c), Cer (Fig. 3d), and GlcCer
(Fig. 3e) in the proband fibroblast cell compared to the
control group, 3.5-fold, 1.5-fold, 2-fold, and 1.4-fold,
respectively.
Increased Numbers of Lysosomes in Saposin A-Deficient
Fibroblasts
Fluorescence microscopic imaging of lysosomal-associated
membrane protein (LAMP1) revealed increased numbers of
lysosomal vesicles in proband fibroblast (Fig. 4c), compared
to healthy family members (Fig. 4a, b). The lysosomal
vesicles in the fibroblast were measured using ImageJ. The
lysosomal intensity measured per cell was 105 for the
father, 96 for the son, and 207.5 for the proband. There are
at least twofold increases in the proband fibroblast.
Increased Autophagosome Numbers in Saposin A-Deficient
Fibroblast
We determined twofold enhanced LC3 and p62 in the
proband fibroblast (Fig. 5b, c, respectively) compared to
healthy family members (father and son) (Fig. 5a). Auto-
phagosome maturation was confirmed by colocalization of
p62 and LC3 (Filimonenko et al. 2007; Pankiv et al. 2007;
Aflaki et al. 2016) (Fig. 5a, d). Autophagosome-lysosome
fusion is impaired in saposin A-deficient fibroblasts. We
demonstrated that the extent of LAMP1/LC3A colocaliza-
tion was reduced (ranging from 50 to 60%) in the proband
fibroblast compared to those of the father and brother
(Fig. 6a, b).
Discussion
This report describes a case of clinical Krabbe disease,
uncommon for the molecular defect sparing the GALC
gene but affecting the PSAP gene by a homozygous
pathogenic variant in the gene’s saposin A domain (saposin
A deficiency, OMIM #611722) highly compatible with
infantile Krabbe disease. Krabbe disease (globoid cell
leukodystrophy, OMIM #245200) was first described by
Krabbe in 1916 and is an autosomal recessive lysosomal
storage disease leading to globoid cell accumulation in
brain tissue. Deficiency of the saposin A molecule leads to
a Krabbe-like manifestation (Spiegel et al. 2005). Follow-
ing the first detection of saposin B by Mehl and Jatzkewitz
in 1964, diseases caused by deficiency of these small
molecules with a very important role in glycosphingolipid
degeneration also began being described (Kishimoto et al.
1992). Since saposin A activates galactosylceramidase
together with saposin C in vitro, a deficiency of saposin
A alone was not thought to lead to a manifestation of
disease (Harzer et al. 1997). However, in their 2001 mouse
study, Matsuda et al. identified saposin A as a major
activator of galactosylceramidase in the brain and showed
that saposin A deficiency results in a Krabbe disease-like
clinical manifestation (Matsuda et al. 2001). Spiegel et al.
reported the first human case of saposin A deficiency in
2005 (Spiegel et al. 2005). Interestingly, Matsuda et al.
observed a late-onset clinical phenotype in the sap A"/"
mice, while the Spiegel et al. case had an early infantile
phenotype. Matsuda et al. attributed this difference to intact
saposin C, which could, in addition to its other functions,
have compensated for saposin A to some extent but was
unable to perform its entire function (Matsuda et al. 2001).
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In contrast, classic infantile Krabbe findings were observed
in Spiegel et al.’s case (2005). Classic infantile Krabbe
findings were also present in our patient. Neuromotor
development was normal until the 4th month, after which a
severe neurodegenerative process commenced. The reason
for this pronounced difference between human and mouse
models is still unclear, although in a study from 2013, Sun
et al. reported a shorter life span of sap A"/" mice and
rapid neurodegeneration based on their own experiences
(Sun and Grabowski 2013; Sun et al. 2003).
Since our patient’s disease was highly compatible with a
clinical manifestation of Krabbe disease but incompatible
with the results of enzymatic and GALC gene analysis, all
enzymatic and genetic investigations were repeated twice
due to a strong suspicion of that disease. Saposin A defect
was primarily considered, and the whole exome sequencing
method was employed to exclude any other Krabbe-like
leukodystrophy. No other relevant change associated with
the clinical manifestation was determined in addition to the
pathogenic variant identified in the PSAP gene. The
considerable similarities between the clinical manifestation
in our case and that published by Spiegel et al. initially
directed us to the hypothesis of saposin A deficiency
(Spiegel et al. 2005). Another problematic point is that our
patient’s enzyme level at dried blood and intraleukocytic
investigation was higher than that expected in classic
disease, but lower than that in normal controls. This is an
unexpected finding considering the nature of the activator
protein. For example, normal arylsulfatase B levels have
been shown in cases of saposin B deficiency (Deconinck
et al. 2008). However, in Spiegel et al.’s study, galacto-
sylceramidase activity at intraleukocytic investigation was
lower than that normally expected and was normal in
fibroblast measurements. It has therefore been postulated
that saposin A is required not only for activation but also
for stabilization and that the enzyme requires an activator
during intraleukocytic measurements. However, due to the
use of in vitro detergents during fibroblast measurement,
the activator does not affect the level of lack of protein
(Spiegel et al. 2005). Additionally, Bradova et al. described
low GALC activity in combined saposin A, B, C, and D
deficiency (Bradova et al. 1993). Saposin A is very likely to
have also in in vitro assays (despite the presence of
detergents or liposomes with the GalCer substrate), not
only in vivo, some activating influence on GALC activity.
Thus, in saposin A deficiency, the missing influence
(missing saposin A interaction with GALC and/or GalCer
substrate) explains lowered GalCer degradation also
in vitro, despite genetically intact GALC enzyme.
The identification of more new cases of saposin A and
other activator protein deficiency will permit a better
understanding of these proteins’ tissue levels and lysosomal
functions and will help clarify the existing uncertainties.
Galactosylsphingosine (psychosine) accumulation is par-
ticularly responsible for neurotoxicity and central nervous
system involvement in Krabbe disease. Psychosine accu-
mulates, not alone, but together with GalCer. However,
accumulation of psychosine has particularly been observed
in brain tissue (Harzer et al. 2002). Psychosine accumula-
tion could not be investigated in our study since the
specimen taken from our patient was fibroblast tissue, and
brain tissue specimens would be needed. Galactosylcer-
amide levels are a significant and specific marker of
insufficient galactosylceramidase activity. In vivo studies
have shown that saposin A also plays a role in the
degradation of GalCer to Cer and also of LacCer to GlcCer
in saposin A-deficient mice (Sun et al. 2013). We detected
significant increases in the levels of GalCer (Fig. 3b),
LacCer (Fig. 3c), Cer (Fig. 3d), and GlcCer (Fig. 3e) in the
proband fibroblast cell compared to the control group,
3.5-fold, 1.5-fold, 2-fold, and 1.4-fold, respectively. The
absence of any mutation in the GALC gene that codes
the protein galactosylceramidase is further evidence that
GalCer accumulation is due to saposin A deficiency. Since
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Fig. 4 Increased number of lysosomes in saposin A patient
fibroblasts (proband) compared to healthy controls (father and
brother). Immunofluorescence signals of LAMP1 were enhanced in
fibroblast of proband (c) compared with her healthy family members
(a, b, respectively). Lysosomes (green) were stained with Anti-Lamp1
antibody. Nuclei (blue) were stained with DAPI. 20! microscopic
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the specimen taken from our patient was obtained from
fibroblast tissue, we think that the accumulation might have
been greater had brain tissue or peripheral nerve tissue
specimens been investigated.
Galactosylceramidase-deficient (Krabbe) skin fibroblasts
have been reported to contain increased LAMP1- and
LAMP2-positive vesicles in their fibroblasts (Lim et al.
2016). We observed increased numbers of lysosomal
vesicles in proband fibroblast (Fig. 4c), compared to
healthy family members (Fig. 4a, b). Increases of at least
twofold occur in the proband fibroblast for lysosomal
intensity. These data clearly indicate increased expression
of LAMP1 and lysosomal vesicles in our saposin A-
deficient fibroblast patient, similar to other lysosomal
storage diseases.
LC3 and p62 are widely used autophagy markers. LC3
binds specifically to autophagic membranes and remains
bound throughout the pathway. p62 functions to deliver
ubiquitinated substrates to the autophagosome. p62 inter-
acts with LC3 and keeps it in the inner and outer
autophagosome membranes. Autophagosomes then fuse
with lysosomes to form autophagolysosomes, which act to
degrade their contents. p62 is also degraded in the
autophagolysosomes (Aflaki et al. 2016). Several studies
have shown accumulation of autophagosome via increased
levels of LC3 and p62 in various lysosomal storage
disorders such as Fabry disease, Gaucher’s disease, and
Pompe disease (Ward et al. 2016). GSL accumulations have
also been shown to affect autophagy in lysosomal storage
disorder, and saposin A deficiency is also the primary factor
for autophagy. Enhancement of two autophagy markers,
p62 and LC3, has been observed in the brains of saposin
A-deficient mice (Sun and Grabowski 2013; Sun et al.
2013). Ours is the first report of impaired autophagy in the
saposin A-deficient patient fibroblast. We determined
twofold enhanced LC3 and p62 in the proband fibroblast
(Fig. 5b, c, respectively) compared to healthy family
members (father and son) (Fig. 5a). These features were
attributed to a block in autophagic flux, since elevated
levels of the autophagosomal marker LC3A and autophagic
substrate p62 were detected in the proband fibroblast.
Autophagosome maturation was confirmed by colocaliza-
tion of p62 and LC3 (Aflaki et al. 2016; Filimonenko et al.
2007; Pankiv et al. 2007; Spiegel et al. 2005) (Fig. 5a, d).
These results show that no problem occurred in the
formation of autophagosomes in both healthy and patient
fibroblasts.
In most lysosomal storage disorders, the autophagic
pathway is impaired by lysosomal dysfunction. Blocking of
the autophagic pathway occurs as a consequence of a
decreased ability of lysosomes to fuse with autophago-
somes (Filimonenko et al. 2007; Settembre et al. 2008;
Ward et al. 2016). Clearance of autophagosomes occurs via
fusion with lysosomes. Here, we investigated the sub-
cellular localization of the lysosomal marker (LAMP1) and
the autophagosomal marker LC3A using fluorescence
microscopy and demonstrated that the extent of LAMP1/
LC3A colocalization was significantly reduced (ranging
from 50 to 60%) in the proband fibroblast compared to
those of the father and brother (Fig. 6a, b). Our data suggest
that accumulation of autophagosomes (Fig. 5b, c) in
saposin A-deficient fibroblasts is due to defective clearance
caused by impaired autophagosome-lysosome fusion
(Fig. 6a, b).
Autophagy has been identified as an important cause of
neurodegeneration in neurodegenerative lysosomal storage
diseases, including Krabbe disease (Ribbens et al. 2014).
Activated autophagy is a significant indicator that the
intracellular coordinated lysosomal expression and regu-
lation (CLEAR) system is also compromised. The neuro-
pathology is thought to occur, not solely in association with
GalCer or glycosphingolipid accumulation but also with
impairment of the CLEAR system (Palmieri et al. 2011).
Ours is also the first study to show the presence of
autophagy in a case of human saposin A deficiency.
De Duve, who first described the lysosome, said that
very little mystery remained regarding its place in genetic
diseases. However, many uncertainties in fact remain. The
role of all activator proteins, including saposin A, inside the
cell, in all likelihood exceeds what we currently know.
Much still remains to be explained concerning the roles of
activator proteins in the lysosomal and degradation path-
ways, their interactions with other proteins, and whether or
not these will have a role to play in the treatment of
lysosomal storage diseases in the future. Further studies and
new cases are now required for these questions to be
answered. Saposin A deficiency may be accurately
described as one of the rarest forms of inborn errors of
metabolism. Our case is the second known report in the
literature. However, there are thought to be a large number
of leukodystrophies still awaiting identification. The most
important step in the diagnosis of saposin A and other
activator protein deficiencies is clinical suspicion, and it is
not possible to identify these diseases in the absence of
such suspicion. Investigation directed toward saposin A
deficiency must be considered when clinical and radio-
logical diagnosis of Krabbe disease is not supported by
enzymatic and genetic methods.
Acknowledgments We thank Centogene AG for whole exome
sequencing analyses.
Conflict of Interest
No conflict of interest was declared by the authors.
JIMD Reports
Financial Disclosure
The authors declared that this study has received no
financial support.
Ethics
All procedures followed were in accordance with the ethical
standards of the responsible committee on human experi-
mentation (institutional) and with the Helsinki Declaration
of 1975, as revised in 2000. Informed consent was obtained
from all patients for being included in the study.
References
Aflaki E, Moaven N, Borger DK, Lopez G, Westbroek W, Chae JJ
et al (2016) Lysosomal storage and impaired autophagy lead to
inflammasome activation in Gaucher macrophages. Aging Cell
15(1):77–88. https://doi.org/10.1111/acel.12409
Bradova V, Smid F, Ulrich-Bott B, Roggendorf W, Paton BC,
Harzer K (1993) Prosaposin deficiency: further characterization
of the sphingolipid activator protein-deficient sibs. Multiple
glycolipid elevations (including lactosylceramidosis), partial
enzyme deficiencies and ultrastructure of the skin in this
generalized sphingolipid storage disease. Hum Genet 92
(2):143–152
Deconinck N, Messaaoui A, Ziereisen F, Kadhim H, Sznajer Y, Pelc K
et al (2008) Metachromatic leukodystrophy without arylsulfatase
A deficiency: a new case of saposin-B deficiency. Eur J Paediatr
Neurol 12(1):46–50. https://doi.org/10.1016/j.ejpn.2007.05.004
Filimonenko M, Stuffers S, Raiborg C, Yamamoto A, Malerod L,
Fisher EM et al (2007) Functional multivesicular bodies are
required for autophagic clearance of protein aggregates associ-
ated with neurodegenerative disease. J Cell Biol 179(3):485–500.
https://doi.org/10.1083/jcb.200702115
Harzer K, Paton BC, Christomanou H, Chatelut M, Levade T,
Hiraiwa M, O'Brien JS (1997) Saposins (sap) A and C activate
the degradation of galactosylceramide in living cells. FEBS Lett
417(3):270–274
Harzer K, Knoblich R, Rolfs A, Bauer P, Eggers J (2002) Residual
galactosylsphingosine (psychosine) beta-galactosidase activities
and associated GALC mutations in late and very late onset
Krabbe disease. Clin Chim Acta 317(1–2):77–84
Kishimoto Y, Hiraiwa M, O'Brien JS (1992) Saposins: structure,
function, distribution, and molecular genetics. J Lipid Res 33
(9):1255–1267
Kolter T, Sandhoff K (2005) Principles of lysosomal membrane
digestion: stimulation of sphingolipid degradation by sphingoli-
pid activator proteins and anionic lysosomal lipids. Annu Rev
Cell Dev Biol 21:81–103. https://doi.org/10.1146/annurev.cell-
bio.21.122303.120013
Lieberman AP, Puertollano R, Raben N, Slaugenhaupt S, Walkley SU,
Ballabio A (2012) Autophagy in lysosomal storage disorders.
Autophagy 8(5):719–730. https://doi.org/10.4161/auto.19469
Lim SM, Choi BO, Oh SI, Choi WJ, Oh KW, Nahm M et al (2016)
Patient fibroblasts-derived induced neurons demonstrate auto-
nomous neuronal defects in adult-onset Krabbe disease. Onco-
target 7(46):74496–74509. https:/ /doi.org/10.18632/
oncotarget.12812
Matsuda J, Vanier MT, Saito Y, Tohyama J, Suzuki K, Suzuki K
(2001) A mutation in the saposin A domain of the sphingolipid
activator protein (prosaposin) gene results in a late-onset, chronic
form of globoid cell leukodystrophy in the mouse. Hum Mol
Genet 10(11):1191–1199
Morimoto S, Martin BM, Yamamoto Y, Kretz KA, O'Brien JS,
Kishimoto Y (1989) Saposin A: second cerebrosidase activator
protein. Proc Natl Acad Sci U S A 86(9):3389–3393
Orsini JJ, Martin MM, Showers AL, Bodamer OA, Zhang XK,
Gelb MH, Caggana M (2012) Lysosomal storage disorder 4+1
multiplex assay for newborn screening using tandem mass
spectrometry: application to a small-scale population study for
five lysosomal storage disorders. Clin Chim Acta 413
(15–16):1270–1273. https://doi.org/10.1016/j.cca.2012.04.012
Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M,
Ballabio A (2011) Characterization of the CLEAR network
reveals an integrated control of cellular clearance pathways. Hum
Mol Genet 20(19):3852–3866. https://doi.org/10.1093/hmg/
ddr306
Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H et al
(2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate
degradation of ubiquitinated protein aggregates by autophagy.
J Biol Chem 282(33):24131–24145. https://doi.org/10.1074/jbc.
M702824200
Ribbens JJ, Moser AB, Hubbard WC, Bongarzone ER, Maegawa GH
(2014) Characterization and application of a disease-cell model
for a neurodegenerative lysosomal disease. Mol Genet Metab 111
(2):172–183. https://doi.org/10.1016/j.ymgme.2013.09.011
Sandhoff K (2016) Neuronal sphingolipidoses: membrane lipids and
sphingolipid activator proteins regulate lysosomal sphingolipid
catabolism. Biochimie 130:146–151. https://doi.org/10.1016/j.
biochi.2016.05.004
Sandhoff R, Hepbildikler ST, Jennemann R, Geyer R, Gieselmann V,
Proia RL et al (2002) Kidney sulfatides in mouse models of
inherited glycosphingolipid disorders: determination by nano-
electrospray ionization tandem mass spectrometry. J Biol Chem
277(23):20386–20398. https://doi.org/10.1074/jbc.M110641200
Seranova E, Connolly KJ, Zatyka M, Rosenstock TR, Barrett T,
Tuxworth RI, Sarkar S (2017) Dysregulation of autophagy as a
common mechanism in lysosomal storage diseases. Essays
Biochem 61(6):733–749. https://doi.org/10.1042/ebc20170055
Settembre C, Fraldi A, Jahreiss L, Spampanato C, Venturi C,
Medina D et al (2008) A block of autophagy in lysosomal
storage disorders. Hum Mol Genet 17(1):119–129. https://doi.
org/10.1093/hmg/ddm289
Spiegel R, Bach G, Sury V, Mengistu G, Meidan B, Shalev S et al
(2005) A mutation in the saposin A coding region of the
prosaposin gene in an infant presenting as Krabbe disease: first
report of saposin A deficiency in humans. Mol Genet Metab 84
(2):160–166
Sun Y, Grabowski GA (2013) Altered autophagy in the mice with
a deficiency of saposin A and saposin B. Autophagy 9
(7):1115–1116. https://doi.org/10.4161/auto.24919
Sun Y, Qi X, Grabowski GA (2003) Saposin C is required for normal
resistance of acid beta-glucosidase to proteolytic degradation.
J Biol Chem 278(34):31918–31923. https://doi.org/10.1074/jbc.
M302752200
Sun Y, Zamzow M, Ran H, Zhang W, Quinn B, Barnes S et al (2013)
Tissue-specific effects of saposin A and saposin B on glyco-
sphingolipid degradation in mutant mice. Hum Mol Genet 22
(12):2435–2450. https://doi.org/10.1093/hmg/ddt096
Ward C, Martinez-Lopez N, Otten EG, Carroll B, Maetzel D, Singh R
et al (2016) Autophagy, lipophagy and lysosomal lipid storage
disorders. Biochim Biophys Acta 1861(4):269–284. https://doi.
org/10.1016/j.bbalip.2016.01.006
JIMD Reports
View publication stats
